Gynecologic Cancers

July 04, 2020

According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.

July 03, 2020

Leslie M. Randall, MD, MAS, discussed the treatment regimens available for an African American patient with ovarian cancer.

July 02, 2020

Bradley Monk, MD, discusses the phase 1b/2 innovaTV 205 trial in patients with recurrent or metastatic cervical cancer.

July 01, 2020

The addition of trastuzumab to chemotherapy in patients with uterine serous carcinoma had superior outcome compared with chemotherapy alone.

June 30, 2020

"Available therapies upon progression after first-line chemotherapy in recurrent or metastatic cervical cancer are limited, and there is a significant unmet need for new treatment options."

June 28, 2020

With multiple treatment options available in the ovarian cancer landscape, experts are now looking for an answer to the challenging question of optimal sequencing.

June 24, 2020

“Cervical cancer screening rates are suboptimal among Asian American women, despite considerable efforts to improve Pap test screening."

June 20, 2020

“We are starting to see more and more patients with recurrent ovarian cancer, we’re treating them much more aggressively in the up-front setting, and we have to face PARP inhibitor resistance in the future.”

June 09, 2020

Mansoor R. Mirza, MD, discusses the results of the PRIMA study of niraparib in patients with advanced ovarian cancer and the evaluation of the starting dose in these patients.

June 08, 2020

In the treatment landscape for advanced cervical cancer, no approved options exist for patients after first-line treatment. Based on phase 2 data, camrelizumab plus apatinib is showing promise.